ReviewCurrent HIV/AIDS reports2007
Confronting proviral HIV infection.
Review in Current HIV/AIDS reports, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- The role of genetic diversity, epigenetic regulation, and sex-based differences in HIV cure research: a comprehensive review.Epigenetics & chromatin · 2025Review
- HIV Reservoirs and Treatment Strategies toward Curing HIV Infection.International journal of molecular sciences · 2024Review
- Structural Basis for Unusual TCR CDR3β Usage Against an Immunodominant HIV-1 Gag Protein Peptide Restricted to an HLA-B*81:01 Molecule.Frontiers in immunology · 2022Article
- Benzolactam-related compounds promote apoptosis of HIV-infected human cells via protein kinase C-induced HIV latency reversal.The Journal of biological chemistry · 2019Article
- Discovery and Development of Anti-HIV Therapeutic Agents: Progress Towards Improved HIV Medication.Current topics in medicinal chemistry · 2019Review
- HIV-1 cellular and tissue replication patterns in infected humanized mice.Scientific reports · 2016Article
- Apoptosis-induced activation of HIV-1 in latently infected cell lines.Retrovirology · 2015Article
- HIV-1 transcription and latency: an update.Retrovirology · 2013Review
- PKC phosphorylates HEXIM1 and regulates P-TEFb activity.Nucleic acids research · 2012Article
- Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies.Retrovirology · 2009Review
- Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection.PloS one · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
The course of HIV infection is arrested by antiretroviral therapy (ART). However, life-long ART is undesirable. To eradicate infection, strategies are needed to deplete the rare population of proviral genomes that persist and reemerge if ART is interrupted. Proviral HIV persists due to the simultaneous deficiency of factors required to allow proviral expression and virion production, and a predominance of factors that obstruct proviral expression. Combining ART with global inducers of T-cell activation has so far failed to eradicate HIV infection. One approach to the selective removal of obstacles to proviral expression, inhibition of the chromatin remodeling enzyme histone deacetylase, has entered clinical testing. Additional approaches may be needed. Ultimately, therapies that eliminate rare cells that persistently express HIV and interrupt low levels of viremia that persist in some patients may be required to render depletion of proviral HIV infection clinically relevant, and lead to the clearance of HIV infection.
Indexed as
Identifiers
17547826What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.